Following the integration of Aesica, Consort Medical has expanded from its leadership position in drug delivery technology in Bespak to become a full-service contract development and manufacturing operation. With strong margin expansion already underway, we raise our EPS CAGR FY16-20e from 9.5% to 10.6%. Our DCF-based and peer group valuation is 1,292-1,399p.
